There is no evidence to suggest that GLP-1 receptor agonists negatively impact fertility
Neves JS, Packer M, Ferreira JP
Whether you are losing weight on semaglutide without exercise or combining it with a structured training program, the lipid improvements tend to track with total weight lost
The same holds if you started a GLP-1 before you ever enrolled in Medicare
However, it may also cause phototoxicity and sensitize skin
Key Points Semaglutide redefining diabetes and obesity treatment 2026: inflection point with patent expiries Manufacturing scalability remains a key constraint Generic entry limited by technical and regulatory barriers Next-generation therapies driving competitive pressure Executive Summary Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), led by semaglutide, have fundamentally transformed the global management of type 2 diabetes mellitus and obesity, delivering substantial improvements in glycemic control, sustained weight reduction, and cardiovascular risk mitigation